An expansion of the Support for clinical Trials Advancing Rare disease Therapeutics (START) program beyond the pilot stage will require dozens of new employees for the US Food and Drug Administration, but Peter Marks believes the additional funding needed would be well-invested.
The START program is intended to provide Operation Warp Speed-like treatment to rare disease therapies. Instead of using the formal...